178 187

Cited 3 times in

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension.

DC FieldValueLanguage
dc.contributor.author강석민-
dc.contributor.author김창수-
dc.date.accessioned2017-02-27T07:36:02Z-
dc.date.available2017-02-27T07:36:02Z-
dc.date.issued2016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/146931-
dc.description.abstractBACKGROUND: The angiotensin receptor antagonist fimasartan lowered blood pressure (BP) in a previous large population study. The purpose of this study was to evaluate whether fimasartan treatment for 3 months affects clinical and home BP variability in addition to reducing BP. METHODS: The study enrolled 1,396 patients (mean age 56.2±10.0 years; males 53.6%) with mild-to-moderate hypertension who had a complete set of home BP measurements (morning and evening) and metabolic risk evaluation. During the 3 months of study, fimasartan alone was used to control BP at a daily dose of 30-120 mg. Clinical and home BP measurements were performed before and after the 3-month treatment. BP variability included beat-to-beat variability (clinical) and day-to-day variability (home). RESULTS: Fimasartan reduced BP after 3 months of treatment. The average reduction of clinical systolic BP (c-SBP) was 15.08±18.36 mmHg (P<0.0001), and the average reduction of morning home SBP (m-SBP) was 11.49±19.33 mmHg (P<0.0001). Beat-to-beat variability as standard deviation (SD) of c-SBP was reduced from 4.56±3.22 to 4.24±3.11 mmHg (P=0.0026). Day-to-day variability as SD of m-SBP was reduced from 7.92±6.74 to 6.95±4.97 mmHg (P<0.0001). Multiple regression analysis revealed an independent association between the change in the SD of c-SBP and the change in c-SBP (P=0.0268) and, similarly, between the change in the SD of m-SBP and the change in m-SBP (P=0.0258), after adjusting for age, sex, body mass index, and change in mean BP. CONCLUSION: This study indicated that 3 months of fimasartan treatment reduced day-to-day BP variability independent of BP reduction in patients with hypertension.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1573~1580-
dc.languageEnglish-
dc.publisherDove Press Limited-
dc.relation.isPartOfDRUG DESIGN DEVELOPMENT AND THERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAngiotensin Receptor Antagonists/chemistry-
dc.subject.MESHAngiotensin Receptor Antagonists/therapeutic use*-
dc.subject.MESHAntihypertensive Agents/therapeutic use*-
dc.subject.MESHBiphenyl Compounds/chemistry-
dc.subject.MESHBiphenyl Compounds/pharmacology*-
dc.subject.MESHBlood Pressure/drug effects*-
dc.subject.MESHHumans-
dc.subject.MESHHypertension/drug therapy*-
dc.subject.MESHPyrimidines/chemistry-
dc.subject.MESHPyrimidines/pharmacology*-
dc.subject.MESHTetrazoles/chemistry-
dc.subject.MESHTetrazoles/pharmacology*-
dc.titleFimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension.-
dc.typeArticle-
dc.publisher.locationNew Zealand-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorMi-Seung Shin-
dc.contributor.googleauthorDae Ryong Kang-
dc.contributor.googleauthorChangsoo Kim-
dc.contributor.googleauthorEun Joo Cho-
dc.contributor.googleauthorKi-Chul Sung-
dc.contributor.googleauthorSeok-Min Kang-
dc.contributor.googleauthorDong-Soo Kim-
dc.contributor.googleauthorSeung Jae Joo-
dc.contributor.googleauthorSeung Hwan Lee-
dc.contributor.googleauthorKyung-Kuk Hwang-
dc.contributor.googleauthorJeong Bae Park-
dc.identifier.doi10.2147/DDDT.S107433-
dc.contributor.localIdA00037-
dc.contributor.localIdA01042-
dc.relation.journalcodeJ02859-
dc.identifier.eissn1177-8881-
dc.identifier.pmid27217724-
dc.subject.keywordangiotensin receptor blockers-
dc.subject.keywordblood pressure variability-
dc.subject.keywordhypertension-
dc.contributor.alternativeNameKang, Seok Min-
dc.contributor.alternativeNameKim, Chang Soo-
dc.contributor.affiliatedAuthorKang, Seok Min-
dc.contributor.affiliatedAuthorKim, Chang Soo-
dc.citation.volume10-
dc.citation.startPage1573-
dc.citation.endPage1580-
dc.identifier.bibliographicCitationDRUG DESIGN DEVELOPMENT AND THERAPY, Vol.10 : 1573-1580, 2016-
dc.date.modified2017-02-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.